[Form 4] Resideo Technologies, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Thermo Fisher Scientific (TMO) filed an 8-K announcing a planned CFO transition.

Senior Vice President & Chief Financial Officer Stephen Williamson will retire effective March 31 2026. To provide continuity, the board has appointed James R. Meyer (age 46), currently Vice President, Financial Operations, to become Senior Vice President & CFO effective March 1 2026. Meyer joined the company in 2009 and has held progressively senior finance roles, including VP of Finance, Customer Channels (2020-2022), before assuming his present post in January 2023; he previously worked at PwC.

No financial results, guidance, debt transactions or other material events were disclosed. The orderly, internally sourced succession suggests minimal operational disruption, although leadership change can introduce short-term uncertainty. Compensation or severance terms were not included in this filing.

Positive

• Orderly transition: nine-month lead time and internal promotion should ensure continuity in financial leadership.
• Experienced successor: James R. Meyer has 16 years at TMO across multiple finance functions, lowering execution risk.

Negative

• CFO departure introduces potential short-term uncertainty until the market assesses Meyer’s performance.
• Lack of financial details: filing provides no insight into compensation arrangements or strategic changes, leaving open questions for investors.

Insights

Financial Analyst

TL;DR: Internal successor limits risk; CFO exit unlikely to alter near-term financial outlook.

The eight-month notice period and one-month overlap give investors comfort that reporting cycles and capital-allocation plans should proceed uninterrupted. Meyer’s 16-year tenure means familiarity with Thermo Fisher’s M&A-driven growth model and integration processes, reducing execution risk. Because no revisions to guidance or strategy were mentioned, I classify the market impact as neutral unless further disclosures surface regarding compensation or strategic shifts.

Corporate Governance Expert

TL;DR: Smooth succession aligns with governance best practices; no red flags detected.

Thermo Fisher adheres to governance norms by announcing the CFO retirement nine months in advance and appointing an experienced internal candidate. The board demonstrates succession planning depth, avoiding a disruptive external search. Absence of any mention of disputes, investigations, or abrupt departures mitigates concern. Nevertheless, investors should monitor upcoming proxy materials for details on Meyer’s compensation package and any post-retirement consulting role for Williamson.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kutz Jeffrey

(Last) (First) (Middle)

16100 N. 71ST STREET

SUITE 550

(Street)

SCOTTSDALE AZ 85254

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESIDEO TECHNOLOGIES, INC. [ REZI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/21/2025		A		26,970	A	$0	26,970	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jeannine J. Lane, Attorney-in-Fact for Jeffrey Kutz	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When will Thermo Fisher Scientific's current CFO retire?

Stephen Williamson will retire effective March 31 2026.

Who has been appointed as the next CFO of TMO?

The board named James R. Meyer, currently VP, Financial Operations, to become CFO effective March 1 2026.

Does the 8-K include any financial results or guidance updates?

No, the filing is limited to the CFO succession and contains no earnings, revenue, or guidance information.

What is James R. Meyer’s background at Thermo Fisher?

Meyer joined in 2009, held various finance roles, was VP of Finance, Customer Channels (2020-2022), and became VP, Financial Operations in 2023.

Is there any information on Stephen Williamson’s severance or consulting role?

The 8-K does not disclose compensation, severance, or post-retirement arrangements.